INS and pneumonia: We observe that the therapy groups receiving insulin monotherapy, insulin therapy combined with statins, biguanides combined with insulin and statins or therapy with DPP-IV inhibitors combined with insulin and statins show higher relative numbers of patients with the outcome of pneumonia during the observational period when compared to other antidiabetic drug therapies.